Procter & Gamble Health Limited has informed the Exchange about Transcript and Link of Recording
PGHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
P&G Health held a virtual analyst/investor meet on June 16, 2025, sharing details of its 9-month fiscal ended March 31, 2025. Sales stood at Rs. 918 crore, up 8% year-on-year, while profit after tax jumped 27% to Rs. 234 crore. Over the past 5 years, the company has delivered consistent high single-digit sales growth, 9% average profit growth, and 200 basis points of net profit margin expansion, supported by Rs. 40+ crore in productivity savings this fiscal. Key brands Neurobion (nearly doubled in 5 years) and Evion (market leader in Vitamin E) drove results, with new launches already contributing high single digits to sales. Exports grew 12% to around Rs. 50 crore, and the Sri Lanka business grew over 30%.
The detailed transcript reinforces management's confidence in its integrated growth strategy, with healthy margin expansion and strong brand momentum. For shareholders, this signals continued operational efficiency and earnings visibility, though near-term growth in the VMS category remains modest with flat volumes and reliance on pricing.